Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.

Translational psychiatry

Volumn 3, Issue , 2013, Pages

  Mondelli, V ^a   Anacker, C ^b   Vernon, A C ^b   Cattaneo, A ^b   Natesan, S ^b   Modo, M ^b   Dazzan, P ^b   Kapur, S ^b   Pariante, C M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; INSULIN; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, RAT; NEUROLEPTIC AGENT; OLANZAPINE;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL MODEL; ARTICLE; DRUG EFFECT; INTRAABDOMINAL FAT; LIVER; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INTRA-ABDOMINAL FAT; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MODELS, ANIMAL; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84879737638     PISSN: None     EISSN: 21583188     Source Type: None    
DOI: 10.1038/tp.2012.138     Document Type: Article

References (0)